Lung cancer in elderly patients

Venuta, Federico; Diso, Daniele; Onorati, Ilaria; Anile, Marco; Mantovani, Sara; Rendina, Erino Angelo

doi:10.21037/jtd.2016.05.20

Cited by 67 publications

(64 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, the median age at NSCLC diagnosis was 70 years . Moreover, a decrease in the incidence of NSCLC in the younger age groups and an increase or plateau in the elderly ones was observed . Therefore, evidence about the clinical benefits of treatment regimens in elderly patients with NSCLC is needed.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma

et al. 2020

View full text Add to dashboard Cite

Background: Previous trials have suggested that elderly patients with non-small-cell lung cancer (NSCLC) could benefit from nanoparticle albumin-bound paclitaxel (nab-paclitaxel). Real-world data on the elderly Chinese population are lacking. This study aimed to analyze the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients (≥65 years) with advanced NSCLC. Methods: This study included 76 patients with a primary diagnosis of IIIB-IV NSCLC from January 2010 to December 2017 at Peking University Cancer Hospital, who received nab-paclitaxel (125 or 130 mg/m 2 i.v.) every three weeks. The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were analyzed. Results: There were 12 patients who received nab-paclitaxel as the first-line treatment (seven also received carboplatin), and 64 received nab-paclitaxel as the latter-line treatment. The overall ORR, DCR, median PFS, and median OS were 14.5%, 69.7%, 5.2 months, and 12.2 months, respectively. The Eastern Cooperative Oncology Group performance status of one and the age of 70-74 years were independently associated with longer OS, while early treatment line of nabpaclitaxel and age of 70-74 years were independently associated with longer PFS. The most common AEs were anemia, leukopenia, gastrointestinal reaction, fatigue, and peripheral neuropathy, which were all manageable. Dose adjustment or treatment discontinuation was encountered in 10 patients because of AEs. The incidence of AEs was not different among age subgroups. Conclusions: Nab-paclitaxel has a good clinical response profile in Chinese elderly patients with stage IIIB-IV NSCLC. Prospective clinical trials are needed to confirm these results. Key pointsSignificant findings of the study: Nanoparticle albumin-bound paclitaxel (nabpaclitaxel) has a good clinical response profile in Chinese elderly (≥65 years) patients with stage IIIB-IV non-small-cell lung cancer (NSCLC), with acceptable and manageable adverse events. What this study adds: Preliminary evidence shows a good clinical response from treatment with nab-paclitaxel in Chinese elderly patients with advanced NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The incidence and prevalence of NSCLC have decreased in younger patients and increased or reached a plateau in elderly patients, highlighting the need for suitable treatment in the elderly subgroup . Older patients often present with poor performance status and/or comorbidities, and many receive only the best supportive care .…”

Section: Introductionmentioning

confidence: 99%

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…As with patients from other age groups, surgical resection at an appropriate stage is the standard of care in patients over 70 years of age. When deciding on the suitability of a patient for surgical treatment, physical performance and comorbidities of the patient are considered rather than his/her age [10]. Consistently, the decision for surgical treatment in our patients was made based on their performance, comorbidities, and patient consent rather than their age.…”

Section: Discussionmentioning

confidence: 99%

A retrospective review of patients over 70 years of age undergoing pneumonectomy for non-small cell lung cancer: 10 years of experience, a cross-sectional study

Yildiz¹,

Inan²,

Çelik³

et al. 2020

Journal of Surgery and Medicine

View full text Add to dashboard Cite

show abstract

“…Clinically, surgery is the rst choice for the treating patients before stage III of NSCLC 7 . According to the abovementioned description, elder patients are major population of lung cancer, which post-surgical infection is frequently lower prognosis than younger patients 8 . Therefore, radiotherapy or chemotherapy usually become adjuvant therapy of surgery to improve prognosis 2 .…”

Section: Introductionmentioning

confidence: 99%

Diterpene 16-hydroxycleroda-3,13-dien-15,16-olide emerges non-canonical autophagic cell death in doxorubicin-resistant lung cancer

Chiu¹,

Shen²,

Wu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The antitumor activity of HCD has been reported in numerous types of cancers. Moreover, the antitumor of HCD could also be applied in non-small-cell lung cancer (NSCLC) cells and further act on doxorubicin-resistant (Dox-R) of NSCLC cells. The underlying anti-cancer mechanism of HCD on Dox-R versus Dox-sensitive (Dox-S) of A549 cells was under this investigation. Methods: Cytotoxicity of HCD against two cell lines (Dox-S and Dox-R) were determined via MTT assay, flow cytometry, and Western blot; and further examination of its anti-cancer efficacy in A549-bearing xenograft mice via orthotopic intratrachea (IT) inoculation. Result: Regardless sensitive and resistant to Dox, HCD could arrest both Dox-S and Dox-R cells at G 2 /M phase without altering the sub-G 1 cycle along with increasing cleaved-PARP. HCD downregulated the mTOR/Akt/PI3K-p85 and PI 3 K-ClassIII/Beclin-1 and upregulated p62/LC3-I/II expressions, further confirmed the cell autophagy after HCD-induced. Morphological observations of the mouse lung sections illustrated that fewer cancer cells accumulated around the trachea while there were less neoplastic activities found in HCD orthotopic treatment mice without liver, kidney and spleen toxicity. Conclusion: HCD exhibited the chemotherapeutic potential for lung cancer in Dox-resistant cells, suggesting natural autophagic inducer HCD provides a promising clue of new drug discovery and development for lung cancer therapy.

show abstract

Lung cancer in elderly patients

Cited by 67 publications

References 67 publications

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma

A retrospective review of patients over 70 years of age undergoing pneumonectomy for non-small cell lung cancer: 10 years of experience, a cross-sectional study

Diterpene 16-hydroxycleroda-3,13-dien-15,16-olide emerges non-canonical autophagic cell death in doxorubicin-resistant lung cancer

Contact Info

Product

Resources

About